Latanoprost plus adjunctive glaucoma medication
ApprovedTerminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma
Conditions
Primary Open Angle Glaucoma
Trial Timeline
Aug 21, 2024 → Jan 20, 2025
NCT ID
NCT06407973About Latanoprost plus adjunctive glaucoma medication
Latanoprost plus adjunctive glaucoma medication is a approved stage product being developed by Sight Sciences for Primary Open Angle Glaucoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06407973. Target conditions include Primary Open Angle Glaucoma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06407973 | Approved | Terminated |
Competing Products
20 competing products in Primary Open Angle Glaucoma